Price
No data yet.
Social Signal Score
Revenue
$315.7KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kuk Hyoun Hwang
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Beta
- 0.57
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -0.48
Financials
Revenue
$315.7K-61.6%Net Income
$-1.00MEBITDA
$932.1KFree Cash Flow
$-2.42M-46918.7%EPS (diluted)
$-0.22Shares Outstanding (diluted)
4.48M-43.5%Operating Expenses
$3.21MCash & Debt
$1.50MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.91M | $-18.01M | $-4.02 |
| 2024 | $3.53M | $-10.33M | $-0.54 |
| 2023 | $0.00 | $403.8K | $0.07 |
| 2022 | $0.00 | $-35.4K | $-0.00 |
| 2021 | $0.00 | $-3.3K | $-0.00 |
| 2020 | $0.00 | $-23.8K | $-0.00 |
Valuation
OSRHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsaccessnewswire.com·6h ago·Negative
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders. To OSR Health Shareholders: I am aware that many of you are watching closely to see what comes next.
View source ↗
Earnings
Wed, Dec 2(in 3 months)
Consensus estimate $-0.27 per share
Typical surprise +42.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.02 vs $-0.28beat
- Wed, May 13$-0.09 vs $-0.29beat
- Tue, Mar 31$-2.02 vs $-0.10miss
- Wed, Nov 12$-0.10 vs $-0.12beat
Estimates and results for OSRH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OSRH officers and directors.
- Bought
- $9.9m
- Sold
- —
2 trades
0 trades
- Bellevue Global Life Science Investors Llcbought
- Hwang Kuk Hyounboughtdirector, 10 percent owner, officer: Chief Executive Officer·430,000 @ $11.50·$4.9m·Feb 14, 2023·filing
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.